The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index; 8 of the 18 sources its claims cite were checked for support.
Teclistamab in Relapsed or Refractory Multiple Myeloma
Open accessAbstract
BACKGROUND: Teclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells. In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma. METHODS: In this phase 1-2 study, we enrolled patients who had relapsed or refractory myeloma after at least three therapy lines, including triple-class exposure to an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody. Patients received a weekly subcutaneous injection of teclistamab (at a dose of 1.5 mg per kilogram of body weight) after receiving step-up doses of 0.06 mg and 0.3 mg per kilogram. The primary end point was the overall response (partial response or better). RESULTS: Among 165 patients who received teclistamab, 77.6% had triple-class refractory disease (median, five previous therapy lines). With a median follow-up of 14.1 months, the overall response rate was 63.0%, with 65 patients (39.4%) having a complete response or better. A total of 44 patients (26.7%) were found to have no minimal residual disease (MRD); the MRD-negativity rate among the patients with a complete response or better was 46%. The median duration of response was 18.4 months (95% confidence interval [CI], 14.9 to not estimable). The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1). Common adverse events included cytokine release syndrome (in 72.1% of the patients; grade 3, 0.6%; no grade 4), neutropenia (in 70.9%; grade 3 or 4, 64.2%), anemia (in 52.1%; grade 3 or 4, 37.0%), and thrombocytopenia (in 40.0%; grade 3 or 4, 21.2%). Infections were frequent (in 76.4%; grade 3 or 4, 44.8%). Neurotoxic events occurred in 24 patients (14.5%), including immune effector cell-associated neurotoxicity syndrome in 5 patients (3.0%; all grade 1 or 2). CONCLUSIONS: Teclistamab resulted in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma. Cytopenias and infections were common; toxic effects that were consistent with T-cell redirection were mostly grade 1 or 2. (Funded by Janssen Research and Development; MajesTEC-1 ClinicalTrials.gov numbers, NCT03145181 and NCT04557098.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 of 18 cited sources checked · 5 supported · 0 flagged · accuracy not yet measured
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In contrast, higher-grade cytokine release syndrome and neurotoxic events have been described after CAR-T administration in patients with multiple myeloma.6,8”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Supportedcites [6] source
Table 2 reports grade 3 or higher cytokine release syndrome in 7 of 128 patients and grade 3 neurotoxic effects in 4 of 128 after ide-cel infusion. The Methods identify the treated population as patients with relapsed and refractory multiple myeloma. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [8] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among 165 patients who received teclistamab, 77.6% had triple-class refractory disease (median, five previous therapy lines).”
- Also stated in: § PATIENTS · plain
“Before study entry, 148 patients (89.7%) had resistance to the previous line of therapy, 128 (77.6%) had triple-class refractory disease, and 50 (30.3%) had penta-drug refractory disease.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > RESULTS
Strength:plain· not yet calibratedn = 165Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § PATIENTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Responses occurred in 104 of 165 patients (63.0%; 95% confidence interval [CI], 55.2 to 70.4).”
- Also stated in: § RESULTS · plain
“the overall response rate was 63.0%”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1)”
- Also stated in: § RESULTS · plain
“The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > RESULTS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan–Meier estimate of maintenance of response for at least 12 months was 68.5% (95% CI, 57.7 to 77.1).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Otherwise, response rates were consistent across most clinically relevant subgroups, including patients with high-risk cytogenetic abnormalities and those with penta-drug refractory disease (Fig. S2).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Hypogammaglobulinemia occurred in 123 patients (74.5%) as determined by means of adverse-event reporting, laboratory analyses (IgG level, <500 mg per deciliter), or both”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 123Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the 65 patients who had a complete response or better, 30 (46%) had no minimal residual disease (Table S4).”
- Also stated in: § RESULTS · plain
“the MRD-negativity rate among the patients with a complete response or better was 46%”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Strength:plain· not yet calibratedn = 65Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Negativity for minimal residual disease (at a threshold of 10−5) was reported in 44 patients (26.7%; 95% CI, 20.1 to 34.1).”
- Also stated in: § RESULTS · plain
“A total of 44 patients (26.7%) were found to have no minimal residual disease (MRD)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“a complete response or better occurred in 65 (39.4%)”
- Also stated in: § RESULTS · plain
“65 patients (39.4%) having a complete response or better”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
- It may state two separate claims as one. 31
- Probably not a substantial claim. 12
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“CAR-T therapy requires that patients have access to specialized care centers and can wait the minimum 4-week period for production, which can result in attrition rates of approximately 10 to 15%,6-8”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Partly supportedcites [6] sourceExperimental — accuracy not yet measured
The Patients section (page not available) reports that 12 of 140 enrolled patients discontinued before ide-cel infusion, an attrition rate of about 8.6%, and that some patients received bridging therapy during manufacturing. It does not establish a minimum four-week production period, a requirement for access to specialized care centers, or that waiting caused the discontinuations. (LLM, conf=0.85)
- Partly supportedcites [7] sourceExperimental — accuracy not yet measured
The Discussion and future perspectives section (page unavailable) says CAR T-cell treatment involves a specialized center and that manufacturing takes several days to weeks, during which disease may progress. It does not establish a minimum four-week production period or an attrition rate of approximately 10–15%. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [8] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Such absence of minimal residual disease has been associated with improved overall survival and progression-free survival in patients with myeloma.14-16”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [14] source
- Supportedcites [15] source
The Introduction states that MRD-negative status is associated with improved progression-free survival (PFS) and overall survival (OS). The Discussion likewise reports prior multiple-myeloma findings for both outcomes; the paper's own OS data were immature, but the claim does not attribute an OS result to this study's analysis. (LLM, conf=0.94)
- Supportedcites [16] source
The Discussion states that MRD negativity is associated with improved survival in both newly diagnosed and relapsed/refractory myeloma. The Introduction links MRD negativity with prolonged progression-free and overall survival, supporting both endpoints in the claim. (LLM, conf=0.90)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03), except for cytokine release syndrome (Table S2) and immune effector cell–associated neurotoxicity syndrome, which were graded according to the criteria of the American Society for Transplantation and Cellular Therapy.12”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > END POINTS AND ASSESSMENTS
What the sources say
- Supportedcites [12] source
The citation supports the exception for CRS and ICANS: the paper sets out consensus grading criteria for both in its ‘Consensus on CRS Grading (Table 2)’ and ‘Consensus on ICANS Grading for Adults’ sections (page not available). The citing study’s choice to grade its other adverse events using CTCAE v4.03 is not attributed to this source. (LLM, conf=0.93)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The primary end point of the phase 2 study was the overall response rate, which was defined as a partial response or better according to the criteria of the International Myeloma Working Group, as assessed by an independent review committee”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > END POINTS AND ASSESSMENTS
What the sources say
- Partly supportedcites [10] sourceExperimental — accuracy not yet measured
The Response criteria section recommends IMWG criteria for clinical trials and endorses the IMWG definition of partial response; the Minimal response section also distinguishes partial response or better from minimal response. The paper does not establish that overall response rate was the primary endpoint of the particular phase 2 study or that an independent review committee assessed it (pages not provided). (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [11] source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Of the 19 deaths due to adverse events in our study, 12 were attributed to Covid-19, which was consistent with the higher mortality observed from Covid-19 in patients with hematologic cancers during this time frame.24”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Supportedcites [24] source
The citation supports the background comparison, not the citing authors’ own count of 12 COVID-19 deaths among 19 adverse-event deaths. The Discussion reports high COVID-19 mortality in patients with hematologic malignancies and says it was substantially higher than in the general population, while cautioning that the estimate may be elevated by the large proportion of hospitalized patients. (LLM, conf=0.92)
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“median, five previous therapy lines”
- Also stated in: § PATIENTS · plain
“Patients had received a median of 5 previous lines of therapy (range, 2 to 14)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > RESULTS
Strength:plain· not yet calibratedn = 165Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Also stated in: § PATIENTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Teclistamab exposure was sustained over the predetermined target level (6 μg per milliliter, based on the upper boundary of an experimentally determined range of the 90% maximal effective concentration) with a low peak-to-trough ratio (Fig. S3).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PHARMACOKINETICS, IMMUNOGENICITY, AND BIOMARKERS
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cytokine release syndrome occurred in 119 patients (72.1%). Most events occurred after step-up and cycle 1 doses, with 6 patients (3.6%) having cytokine release syndrome in cycle 2 or later. Most events of cytokine release syndrome were grade 1 or 2 in severity and fully resolved, except for one grade 3 event”
- Also stated in: § RESULTS · plain
“cytokine release syndrome (in 72.1% of the patients; grade 3, 0.6%; no grade 4)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 119Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Response rates were lower in patients with extramedullary disease, stage III disease, and at least 60% marrow replacement by plasma cells and were higher in those who had received no more than three previous lines of therapy.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“thrombocytopenia (in 66 [40.0%])”
- Also stated in: § RESULTS · plain
“thrombocytopenia (in 40.0%; grade 3 or 4, 21.2%)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 66Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 68 patients (41.2%) died, with most deaths (41) attributed to progressive disease (Table S9). Nineteen patients died from adverse events, including 12 deaths from coronavirus disease 2019 (Covid-19). Five deaths were considered by investigators to be related to teclistamab”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, reductions in soluble BCMA levels occurred during the first 4 cycles of treatment in 63 of 72 evaluable patients (88%) who had a partial response or better, whereas all the evaluable patients who did not have a response (9 of 9 patients) had increased levels of soluble BCMA.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PHARMACOKINETICS, IMMUNOGENICITY, AND BIOMARKERS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 98 patients (59.4%) received at least 6 months of teclistamab treatment, and 79 patients (47.9%) received at least 9 months of treatment.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PATIENTS
Strength:plain· not yet calibratedn = 98Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All 165 patients reported having an adverse event (Table 2 and Table S5), which were grade 3 or 4 in 156 patients (94.5%).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Five patients had a total of 9 events of immune effector cell–associated neurotoxicity syndrome, all either grade 1 or 2. Of these 9 events, 7 were concurrent with cytokine release syndrome, and all 9 events resolved without discontinuation or dose reduction.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“neutropenia (in 117 patients [70.9%])”
- Also stated in: § RESULTS · plain
“neutropenia (in 70.9%; grade 3 or 4, 64.2%)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 117Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Injection-site reactions were reported in 60 patients (36.4%); all such events were grade 1 or 2.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 60Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median time until the onset of cytokine release syndrome was 2 days (range, 1 to 6) after the most recent dose, and the median duration was 2 days (range, 1 to 9).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Investigator-assessed neurotoxic events, including immune effector cell–associated neurotoxicity syndrome, were reported in 24 patients (14.5%).”
- Also stated in: § RESULTS · plain
“Neurotoxic events occurred in 24 patients (14.5%), including immune effector cell–associated neurotoxicity syndrome in 5 patients (3.0%; all grade 1 or 2).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 24Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“anemia (in 86 [52.1%])”
- Also stated in: § RESULTS · plain
“anemia (in 52.1%; grade 3 or 4, 37.0%)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 86Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median time until the first response was 1.2 months (range, 0.2 to 5.5), and the median time until a best response was 3.8 months (range, 1.1 to 16.8).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Strength:plain· not yet calibratedn = 165Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“One patient had a dose reduction during cycle 21 because of recurrent neutropenia, and 104 patients (63.0%) skipped a dose because of adverse events. Two patients discontinued teclistamab because of adverse events (grade 3 adenoviral pneumonia and grade 4 progressive multifocal leukoencephalopathy).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As of March 16, 2022, 70 patients (42.4%) were continuing to receive treatment (Fig. S1), with a median treatment duration of 8.5 months (range, 0.2 to 24.4).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PATIENTS
Strength:plain· not yet calibratedn = 70Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Infections occurred in 126 patients (76.4%); 74 patients (44.8%) had grade 3 or 4 infections.”
- Also stated in: § RESULTS · plain
“Infections were frequent (in 76.4%; grade 3 or 4, 44.8%).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 126Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The overall depth of response was highlighted by the observation that 26.7% of the patients were found to have no minimal residual disease at a sensitivity level of 10−5; these patients made up 82% of those in whom minimal residual disease could be evaluated.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cytopenias and infections were common; toxic effects that were consistent with T-cell redirection were mostly grade 1 or 2.”
- Also stated in: § DISCUSSION · plain
“Toxic effects were also common but were mainly of low grade and reversible.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > CONCLUSIONS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § DISCUSSION · plain
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The sponsor established a safety evaluation team to monitor patient safety throughout the phase 1 study. In phase 2, safety was monitored through continuous review by the sponsor.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, subgroup analyses suggest that patients who have received no more than three previous therapy lines may have a better response rate than those who have received more than three therapies, a finding that supports the use of teclistamab in earlier therapy lines (although the confidence intervals for this finding are wide).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Teclistamab redirects CD3+ T cells to BCMA+ myeloma cells, resulting in T-cell activation and subsequent lysis and death of BCMA+ cells.18”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [18] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study was conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Council for Harmonisation.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Toxic effects were also common but were mainly of low grade and reversible.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median relative dose intensity was high, and dose reductions and discontinuations owing to adverse events were infrequent.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The safety and efficacy populations for this analysis included all the patients who had received at least one dose of teclistamab at the recommended phase 2 dose in phase 1 or phase 2 as of September 7, 2021.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STATISTICAL ANALYSIS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Response rates were also compared across various prespecified subgroups, including those defined according to cytogenetic risk, refractory status, and number of previous lines of therapy.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STATISTICAL ANALYSIS
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“For phase 2, we determined that a sample size of 100 patients would provide a power of at least 85% to establish an overall response rate of more than 30% at a one-sided significance level of 0.025, assuming an overall response rate of at least 45%.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STATISTICAL ANALYSIS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“Adverse events in this phase 1–2 trial were common and included low-grade cytokine release syndrome and grade 3 or 4 cytopenia and infection in a patient population that has an increased susceptibility to infection due to the immunodeficiency associated with myeloma and immunosuppressive effects of previous myeloma therapies.23”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [23] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Negativity for minimal residual disease was assessed by next-generation sequencing of DNA obtained from bone marrow aspirate (clonoSEQ assay, version 2.0 [Adaptive Biotechnologies]) with a threshold of 10−5 cells.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > END POINTS AND ASSESSMENTS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study protocol, amendments, and relevant documents were approved by the local independent ethics committee or institutional review board at each study site. All the patients provided written informed consent.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All the authors affirm that the trial was conducted in accordance with the study protocol and vouch for the accuracy and completeness of the data.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper relies on this without support.
Teclistamab is readily available.
“Teclistamab is readily available and has been associated with rapid onset of response after a median of approximately 1 month of treatment.”
The paper relies on this without support.
No CD3-redirecting therapy has been approved for the treatment of myeloma.
“Although clinical proof of concept has been obtained for other CD3-redirection platforms in other indications,19-21 no CD3-redirecting therapy has been approved for the treatment of myeloma.”
The paper relies on this without support.
Cross-trial comparisons are challenging to interpret owing to differences in study design and patient populations.
“Although cross-trial comparisons are challenging to interpret owing to differences in study design and patient populations, the response rates observed with teclistamab (63%) compare favorably with those of belantamab mafodotin”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Two BCMA-targeting bispecific antibodies, teclistamab and elranatamab, have been approved for use in patients with relapsed myeloma who have received at least 4 prior regimens.91,92”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [91]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“A number of BCMA-directed therapies, including belantamab mafodotin, idecabtagene vicleucel (ide-cel), ciltacabtagene autoleucel (cilta-cel) and teclistamab, have shown efficacy in clinical trials and are approved for the treatment of relapsed or refractory multiple myeloma4–9.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, patients with advanced disease stage (R-ISS stage III) have consistently shown poorer outcomes irrespective of the therapy received4–6,19–22.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In comparison to other BCMA-targeted T-cell-redirecting therapies, the rate of hematologic AEs with elranatamab was similar or lower after a similar follow-up4–6.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and favorable to the BCMA-targeting antibody–drug conjugate, belantamab mafodotin (ORR 32%, median DOR 11.0 months and median PFS 2.8 months) after a median follow-up of 12.4 months4,9,19,23.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Teclistamab and elranatamab are bispecific antibodies produce an immunotherapeutic effect by binding to BCMA on myeloma cells on one arm and CD3 on T cells with the other.91,92”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [91]
The cited source says what the claim attributes to it.
In the citing paper
“The primary endpoint in phase 2 was overall response rate per IMWG criteria,11 based on independent committee review, which was defined as the proportion of patients who had a partial response or better.”
From Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. (2025) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Teclistamab, a bispecific antibody targeting CD3×BCMA,6 demonstrated deep and durable responses in heavily pretreated RRMM in the phase 1/2 MajesTEC-1 study.7,8”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“Cytokine release syndrome incidence was lower than that observed with teclistamab monotherapy in MajesTEC-1 (60.1% vs. 72.1%, respectively),8 with most events being grade 1 and occurring during the step-up dosing schedule.”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“In this trial, 165 RRMM patients were treated with Teclistamab, and the following key outcomes were observed 63.0% ORR, 58.8% VGPR, and 39.4% CR. These results demonstrate the significant clinical activity of Teclistamab in RRMM patients who have received multiple prior lines of therapy. The high ORR, VGPR rate, and CR rate indicate substantial anti-myeloma activity of Teclistamab. Additionally, t”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [209]
The cited source says what the claim attributes to it.
In the citing paper
“The lower response rate observed in patients with extramedullary disease reflects the historically poor prognosis in this subgroup and has also been observed with other anti-BCMA-targeted agents such as belantamab mafodotin and teclistamab4,19.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Citations
Cites
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationIdecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560
Self-citationBerdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Self-citationRajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Self-citationMultiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationLonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Self-citationVijenthira, A., Gong, I. Y., Fox, T. A., Booth, S., Cook, G., Fattizzo, B., Martín-Moro, F., Razanamahery, J., Riches, J. C., Zwicker, J., et al. (2020) · Blood · doi:10.1182/blood.2020008824 · Cited by 625
Shah, N., Chari, A., Scott, E., Mezzi, K., & Usmani, S. Z. (2020) · Leukemia · doi:10.1038/s41375-020-0734-z · Cited by 490
Self-citationBispecific T‐cell engagers for cancer immunotherapy
Huehls, A. M., Coupet, T. A., & Sentman, C. L. (2014) · Immunology and Cell Biology · doi:10.1038/icb.2014.93 · Cited by 478
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,251
Blanquart, E., Ekren, R., Rigaud, B., Joubert, M.-V., Baylot, V., Daunes, H., Cuisinier, M., Villard, M., Carrié, N., Mazzotti, C., et al. (2024) · Blood · doi:10.1182/blood.2023023529 · Cited by 26
Sandahl, T. B., Soefje, S. A., Fonseca, R., et al. (2024) · JCO Oncology Practice · doi:10.1200/op-24-00489 · Cited by 22
Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
Lee, J. C., Johnson, W. T., Hines, M., & Shah, N. N. (2025) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2025.02.005 · Cited by 27
Gay, F., Marchetti, E., & Bertuglia, G. (2025) · Hematological Oncology · doi:10.1002/hon.70067 · Cited by 30
Razzo, B. M., Midha, S., Portuguese, A. J., Grajales-Cruz, A. F., Corraes, A. D. M. S., Costello, P., Liu, Y., Sperling, A. S., Nadeem, O., Dima, D., et al. (2025) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-24-0354 · Cited by 25
Self-citationMechanisms and treatment of cancer therapy-induced peripheral and central neurotoxicity
Karschnia, P., Nelson, T. A., & Dietrich, J. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00863-2 · Cited by 34
“BiTes seem to induce a lower rate of ICANS than CAR-T cell therapy 19,20 .”
T cell engagers emerge as a compelling therapeutic modality
Baeuerle, P. A., Sauer, K., Grieshaber‐Bouyer, R., & Michaelson, J. S. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20251652 · Cited by 25
Regulatory T cells hamper the efficacy of T-cell-engaging bispecific antibody therapy
Casey, M., Lee, C., Kwok, W. Y., Law, S. C., Corvino, D., Gandhi, M. K., Harrison, S. J., & Nakamura, K. (2023) · Haematologica · doi:10.3324/haematol.2023.283758 · Cited by 25
BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them
Rees, M. J., & Kumar, S. K. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2284088 · Cited by 22
“…with ≥ three prior lOt (median 5) received teclistamab until intolerance or disease progression, the ORR was 63% with median PFS of 11 months [32]. elranatamab is administered subcutaneously on a weekly or biweekly schedule and obtained FDA approval in August 2023 following the phase 2…”
BackgroundMethodTherapeutic progress in relapsed/refractory multiple myeloma
Chen, Q., Zhang, M., Zheng, S., Tong, Y., & Tan, Y. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05730-y · Cited by 26
“…effects; however, further long-term trials are needed to determine whether teclistamab is also affected by soluble BCMA levels, which have been shown to interfere with the activity of BCMA-targeted drugs; moreover, the shedding of BCMA targets after treatment can lead to relapse [ 42, 61, 62].”
Rees, M. J., Mammadzadeh, A., Bolarinwa, A. B., Elhaj, M., Bohra, A., Bansal, R., Ailawadhi, S., Parrondo, R. D., Chhabra, S., Khot, A. S., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01081-z · Cited by 23
“While consistent with other reports [7, 15 – 18], clinicians should interpret this in the appropriate clinical context.”
BackgroundResultInfluentialCardiovascular toxicities associated with novel cellular immune therapies
Munir, M., Sayed, A., Addison, D., & Epperla, N. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013849 · Cited by 27
“On the contrary, a lower percentage of BTE patients experienced CRS, with reported rates of up to 16% in B-cell acute lymphoblastic leukemia (B-ALL), 6 ~70% in multiple myeloma 7 and ranging from 44% to ~70% in B-cell lymphoma 8-10 ; additionally, when CRS occurs with BTE therapy, it is less severe.”
Guégan, M., Bichon, M., Chaput, N., Houot, R., & Lemoine, J. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115145 · Cited by 23
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy
Touzeau, C., Mina, R., Quach, H., Hungria, V., Bhutani, D., Chen, W., Kumar, S. S., Chaulagain, C. P., Dimopoulos, M. A., Bahlis, N. J., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2603870 · Cited by 29
Self-citationHow We Manage Newly Diagnosed Multiple Myeloma With Circulating Tumor Cells
van de Donk, N. W. C. J. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.02114 · Cited by 21
Self-citationMonoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma
Luca, F. D., Allegra, A., Chio, C. D., Previti, S., Zappalà, M., & Ettari, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043136 · Cited by 21
“In the dose-defining phase 1 study [79,80], teclistamab showed promising efficacy in patients with RRMM.”
BackgroundNew Developments in Myeloma Treatment and Response Assessment
Kraeber‐Bodéré, F., Jamet, B., Bezzi, D., Zamagni, E., Moreau, P., & Nanni, C. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264972 · Cited by 21
“Finally, bispecific antibodies represent a promising and effective therapeutic approach in MM and have been recently approved by the European Medicines Agency in the relapse setting (53).”
BackgroundSelf-citationManaging side effects: guidance for use of immunotherapies in multiple myeloma
Liang, E. C., & Sidana, S. (2023) · Hematology · doi:10.1182/hematology.2023000435 · Cited by 22
Self-citationPasvolsky, O., Wang, Z., Milton, D. R., Tanner, M. R., Bashir, Q., Srour, S. A., Saini, N. Y., Lin, P. Y., Ramdial, J., Nieto, Y. L., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01062-2 · Cited by 22
Mol, I., Hu, Y., LeBlanc, T. W., Cappelleri, J. C., Chu, H., Nador, G., Aydin, D., Schepart, A., & Hlavacek, P. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2313628 · Cited by 21
“The baseline characteristics and response outcome data for the MajesTEC-1 study were obtained from Moreau et al. [25].”
MethodInfluentialTreatment of relapsed/refractory MCL
Silkenstedt, E., & Dreyling, M. H. (2024) · Blood · doi:10.1182/blood.2023022353 · Cited by 24
Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma
Pu, J., Liu, T., Sharma, A., Jiang, L., Wei, F., Ren, X., Schmidt‐Wolf, I. G. H., & Hou, J. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00576-6 · Cited by 23
“Despite a lower response rate compared to some CAR-T treatments, teclistamab offers a safer profile and easier production [261, 262].”
ResultSafety and Efficacy of Teclistamab in Patients With Relapsed or Refractory AL Amyloidosis
Stalker, M., Garfall, A. L., Cohen, A. D., et al. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14348 · Cited by 20
Self-citationWaldschmidt, J. M., Rasche, L., Kortüm, K. M., & Einsele, H. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.11.012 · Cited by 23
Teclistamab in relapsed systemic sclerosis after autologous haematopoietic stem cell transplantation
Siegert, E., Biesen, R., Dzamukova, M. R., et al. (2025) · Annals of the Rheumatic Diseases · doi:10.1016/j.ard.2025.01.043 · Cited by 20
Tix, T., Alhomoud, M., Shouval, R., Iacoboni, G., Cliff, E. R. S., Hansen, D. K., Usmani, S. Z., Salles, G. A., Perales, M., dos Santos, D. M. C., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.048 · Cited by 22
Self-citationAmoozgar, B., Bangolo, A., Habibi, M., Cho, C., & Goy, A. H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115319 · Cited by 21
“In the MajesTEC-1 study of teclistamab, a BCMA × CD3 bispecific antibody, Grade ≥ 3 neutropenia was reported in 51.1% of patients, anemia in 37.8%, and thrombocytopenia in 21.5% [102].”
InfluentialTalquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Hadidi, S. A., Szabó, A., Lal, B. M., Bag, A., Zhen, S., Ogunsesan, Y., Annyapu, E., Dhakal, B., Bhutani, D., Thanendrarajan, S., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01386-7 · Cited by 20
Kang, Y., Sundaramoorthy, P., Gasparetto, C., et al. (2022) · Annals of Hematology · doi:10.1007/s00277-022-05056-7 · Cited by 20
Raje, N. S., Mateos, M., Iida, S., & Reece, D. E. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00804-y · Cited by 20
“of prior lines of therapy): AMG420 (7 [3–14]), [78], AMG701 (6 [1–25]), [79], CC-93269 (5 [3–13]), [80], teclistamab (6 [2–14]), [81], REGN5458 (not available (NA) [3-NA]), [82], elranatamab (8 [NA]), [83], and TNB-383B (7 [4–13].”
Self-citationTalbot, A., Bobin, A., Tabone, L., Lambert, J., Boccaccio, C., Deal, C., Petillon, M., Allangba, O. T., Agapé, P., Arnautou, P., et al. (2023) · Haematologica · doi:10.3324/haematol.2022.281772 · Cited by 20
Self-citationde la Rubia, J., Alonso, R., Clavero, E., Askari, E., García, A., Antón, C., Fernández, M., Escalante, F., García, A., Ríos, R., et al. (2023) · Cancers · doi:10.3390/cancers15112964 · Cited by 22
Teclistamab‐cqyv in multiple myeloma
Martino, E. A., Bruzzese, A., Labanca, C., Mendicino, F., Lucia, E., Olivito, V., Neri, A., Morabito, F., Vigna, E., & Gentile, M. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14121 · Cited by 22
“In the pivotal study 25 the cohort analyzed was mainly represented by heavily pre-treated patients who received up to 14 previous lines of therapy, with nearly 78% of the being triple-class refractory.”
BackgroundKeller, A., Reiman, L. T., de Acha, O. P., Parzych, S. E., Forsberg, P. A., Kim, P., Bisht, K., Wang, H., de Velde, H. V., & Sherbenou, D. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0434 · Cited by 14
Sharma, A., Gupta, K., Mishra, A., Lofland, G., Marsh, I. R., Kumar, D., Ghiaur, G., Imus, P. H., Rowe, S. P., Hobbs, R. F., et al. (2024) · Advanced Science · doi:10.1002/advs.202308617 · Cited by 18
Pillarisetti, K., Yang, D., Luistro, L. L., Yao, J., Smith, M. L., Vulfson, P., Testa, J. S., Ponticiello, R. P., Brodeur, S. R., Heidrich, B. J., et al. (2025) · Blood · doi:10.1182/blood.2025030027 · Cited by 24
Lee, H. C., Zonder, J. A., Dhodapkar, M. V., Jagannath, S., Hoffman, J. E., Suvannasankha, A., Shah, M. R., Lentzsch, S., Baz, R., Maly, J. J., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.11.004 · Cited by 22
Self-citationJelinek, T., Žihala, D., Zabaleta, A., Kostopoulos, I. V., Souček, O., Venglár, O., Moreno, C., Fotiou, D., Radova, E., Tamariz‐Amador, L., et al. (2025) · Blood · doi:10.1182/blood.2025029572 · Cited by 20
Self-citationFDA Approvals of Biologics in 2022
Martins, A. C., Alberício, F., & de la Torre, B. G. (2023) · Biomedicines · doi:10.3390/biomedicines11051434 · Cited by 20
Khanam, R., Faiman, B. M., Batool, S., Najmuddin, M. M., Usman, R. M., Kuriakose, K., Ahmed, A., Rehman, M. E. U., Roksana, Z., Syed, Z., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175539 · Cited by 20
“CRS usually occurs 1–14 days after CAR-T therapy and 1–6 days after teclistamab administration [66,67].”
BackgroundLutz, S., Klausz, K., Albici, A.-M., Ebinger, L., Sellmer, L., Teipel, H., Frenzel, A., Langner, A., Winterberg, D., Krohn, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1227572 · Cited by 19
Gong, Z., Umoru, G., Monge, J., Shah, N. N., Mohyuddin, G. R., Radhakrishnan, S. V., Chakraborty, R., Rasche, L., Schinke, C., D’Souza, A., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01023-9 · Cited by 19
“Similarly, clinical trial of bsAbs also reported cases of NRM related to COVID-19 infection, hepatic failure, and PML [3, 4].”
BackgroundChakraborty, R., Cheruvalath, H., Patwari, A., Szabó, A., Schinke, C., Dhakal, B., Lentzsch, S., D’Souza, A., Mohyuddin, G. R., Julian, K. L., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01114-7 · Cited by 20
“[BCMA] and G-protein-coupled receptor class C group 5 member D [GPRC5D] have demonstrated deep and durable responses in patients with relapsed/refractory multiple myeloma [MM], with single-agent response rates from 57 – 71% [1 – 6].”
BackgroundRenal AL Amyloidosis: Updates on Diagnosis, Staging, and Management
Shafqat, A., Elmaleh, H., Mushtaq, A., Firdous, Z., Ashruf, O. S., Mukhopadhyay, D., Ahmad, M., Ahmad, M., Raza, S., & Anwer, F. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061744 · Cited by 18
“Teclistamab, a BCMA x CD3 bispecific T-cell engager, has recently been approved by the FDA for the treatment of relapsed and refractory multiple myeloma, achieving an over-all response rate of 63% and MRD negativity in 26% of patients [81].”
BackgroundAnderson, G. S. F., & Chapman, M. A. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.07.028 · Cited by 20
Sassine, J., Siegrist, E. A., & Chemaly, R. F. (2025) · Viruses · doi:10.3390/v17010133 · Cited by 19
“In multiple myeloma, some of the BsAb constructs target BCMA (teclistamab, erlanatamab), whereas others target non-BCMA epitopes on plasma cells such as GPRC5D (talquetamab) [47–49].”
Kazandjian, D. G., Kowalski, A., & Landgren, O. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2113532 · Cited by 19
Martin, Y. S., Franz, J. K., Agha, M., & Lazarus, H. (2023) · Blood reviews · doi:10.1016/j.blre.2023.101095 · Cited by 18
Costa, B. A., Mouhieddine, T. H., Ortiz, R. J., & Richter, J. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104040 · Cited by 18
O’Neill, C. A., & van de Donk, N. W. C. J. (2023) · eJHaem · doi:10.1002/jha2.729 · Cited by 17
Self-citationMartin, T. G., Madduri, D., Pacaud, L. B., & Usmani, S. Z. (2023) · Future Oncology · doi:10.2217/fon-2022-1317 · Cited by 20
Self-citationHartley-Brown, M. A., Mo, C. C., Nadeem, O., Midha, S., Laubach, J. P., & Richardson, P. G. G. (2024) · Cancers · doi:10.3390/cancers16061166 · Cited by 22
“…receptor (CAR) T-cell therapies idecabtagene vicleucel (ide-cel) [22,23] and ciltacabtagene autoleucel (cilta-cel) [24,25]; the bispecific antibodies/T-cell engagers teclistamab [26], talquetamab [27], and elranatamab [28]; and, in Europe, the antibody–drug conjugate belantamab mafodotin [29].”
BackgroundParrondo, R. D., Ailawadhi, S., & Cerchione, C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1394048 · Cited by 21
Ikeda, D., Aikawa, S., Misono, C., et al. (2024) · Blood · doi:10.1182/blood.2024026028 · Cited by 18
Moreau, P., Mateos, M., García, M. E. G., Einsele, H., Stefano, V. D., Karlin, L., Lindsey-Hill, J., Besemer, B., Vincent, L., Kirkpatrick, S., et al. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02738-0 · Cited by 18
Self-citationPerrot, A., Delimpasi, S., Spanoudakis, E., Frølund, U. C., Belotti, A., Oriol, A., Moreau, P., McFadden, I., Xia, Q., Arora, M., et al. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2322030 · Cited by 17
“…(CAR-T) and immune cell–redirecting therapies have recently become available, yet these have been approved for patients with ≥3 prior lines of therapy and are associated with logistical challenges and risk mitigation requirements that may limit their use to a subset of RRMM patients [1,7–10].”
BackgroundSelf-citationDima, D., Vazquez-Martinez, M. A., Davis, J. A., Goel, U., Afrough, A., Sannareddy, A., Pasvolsky, O., Razzo, B. M., Banerjee, R. K., Khouri, J., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01314-9 · Cited by 18
Self-citationVianna, P. M. M., Chakraborty, R., Hossain, S., Bhutani, D., Miller, S., Rossi, A., Cuddy, S. A. M., Falk, R. H., Lentzsch, S., Laubach, J. P., et al. (2025) · Blood · doi:10.1182/blood.2025028383 · Cited by 21
Schinke, C., Rodríguez‐Otero, P., van de Donk, N. W. C. J., Lipe, B. C., Lavi, N., Rasche, L., Parekh, S. S., Oekelen, O. V., Vishwamitra, D., Skerget, S., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016613 · Cited by 20
Self-citationvan de Donk, N. W. C. J., Moreau, P., Miguel, J. F. S., Mateos, M., Dimopoulos, M. A., Zweegman, S., Gay, F., Engelhardt, M., Mina, R., Zamagni, E., et al. (2025) · HemaSphere · doi:10.1002/hem3.70260 · Cited by 20
Self-citationLiu, D., Qi, X., Wei, X., Zhao, L., Wang, X., Li, S., Wang, Z., Shi, L., Xu, J., Mei, H., et al. (2022) · Theranostics · doi:10.7150/thno.75037 · Cited by 17
“Indeed, several clinical successes of bsAb therapies have been reported; among the eight approved bsAbs, Blincyto (blinatumomab), Removab (catumaxomab), Kimmtrak (tebentafusp-tebn), Mosunetuzumab (Lunsumio) and Teclistamab (Tecvayli) which redirect T-cell specificity, have dominated the novel cancer therapies develope…”
Mateos, M., Chari, A., Usmani, S. Z., et al. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.02.006 · Cited by 17
Self-citationOutcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma
Pasvolsky, O., Ghanem, S., Milton, D. R., Masood, A., Tanner, M. R., Bashir, Q., Srour, S. A., Saini, N., Lin, P. Y., Ramdial, J., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.08.031 · Cited by 17
Noori, M., Yazdanpanah, N., & Rezaei, N. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03045-y · Cited by 16
“For seven BsAbs, the plasma-cell recognition target was BCMA [12–16, 18, 20], while Fc receptorlike protein 5 (FcRH5) was targeted for one of the BsAbs [17, 22], and G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D) for the other one [19, 21].”
BackgroundYamamoto, C., Minakata, D., Yokoyama, D., Furuki, S., Noguchi, A., Koyama, S., Oyama, T., Murahashi, R., Nakashima, H., Ikeda, T., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.10.001 · Cited by 21
Martin, T. G., Moreau, P., Usmani, S. Z., Garfall, A. L., Mateos, M., Miguel, J. F. S., Oriol, A., Nooka, A. K., Rosiñol, L., Chari, A., et al. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.11.001 · Cited by 17
Self-citationNovel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment
Morè, S., Corvatta, L., Manieri, V. M., Morsia, E., Poloni, A., & Offidani, M. (2023) · Pharmaceuticals · doi:10.3390/ph16111628 · Cited by 19
“Pneumonia represents the most common clinically documented infection, and it occurred in 18% of patients treated with teclistamab [74] and in 16.3% of those receiving elranatamab [75], so patients receiving BsAbs should be closely monitored for early diagnosis and treatment of these infections.”
BackgroundInfluentialCurrent use of CAR T cells to treat multiple myeloma
Firestone, R., & Mailankody, S. (2023) · Hematology · doi:10.1182/hematology.2023000434 · Cited by 18
Immune status and selection of patients for immunotherapy in myeloma: a proposal
Dhodapkar, M. V. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011242 · Cited by 21
“5,6 Further studies are needed to better understand the mechanisms by which TCEs redirect and sustain anti-MM immunity.”
BackgroundMitigating time toxicity in lymphoma and multiple myeloma
Di, M., Su, C. T., Cowan, A. J., Gopal, A. K., & Banerjee, R. K. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2352086 · Cited by 18
“…until progression, patients may remain on parenteral dosing every 1-2 weeks for several months or even years under current dosing schemas (table 2) [86–91]. thankfully, both fixed-duration regimens for cevostamab and teclistamab are now under investigation [92,93]. in addition, several ongoing…”
Iida, S., Ito, S., Yokoyama, H., Ishida, T., Nagai, Y., Handa, H., Ito, S., Kamei, Y., Nakamura, M., & Suzuki, K. (2024) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyae068 · Cited by 16
“…low incidence of neurotoxic effects was reported for elranatamab in the BCMA-naive MagnetisMM-3 population, where ICANS (all grade 1 or 2) occurred in 3.4% of patients, and for other BCMA-targeting bispecific antibodies such as teclistamab, where ICANS incidence was 3.0% (all grade 1 or 2) (31,40).”
BackgroundResultInfluentialRichardson, T., Schütte, D., Kobbe, G., Baermann, B.-N., Holderried, T., Schmitz, F., Crysandt, M., Hallek, M., Scheid, C., Holtick, U., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015008 · Cited by 16
“In total 31.6% of the occurring infections were vaccine preventable, at least regarding severity of disease, including infections by Haemophilus in fl uenzae , in fl uenza, respiratory syncytial virus, and severe acute respiratory syndrome coronavirus 2.”
InfluentialSteinhardt, M., Schaefers, C., Leypoldt, L., Blau, I., Harzer, M., Zhou, X., Riedhammer, C., Kamili, A., Kosch, R., Topp, L. S., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01330-9 · Cited by 17
“With the BCMA-targeted bsAB teclistamab, the ORR was 36% in the pivotal MajesTEC-1 study [19] and 47% in a real-world analysis [20].”
Golmohammadi, M., Raza, S., Albayyadhi, M., Sholehrasa, H., Khouri, J., Williams, L., Hansen, D. K., Moradi, A., Xu, X., Albliwi, M., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01334-5 · Cited by 18
Individualised neoantigen cancer vaccine therapy
Terai, M., & Sato, T. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02463-7 · Cited by 17
Wang, X., Zhao, A., Zhu, J., & Niu, T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1348955 · Cited by 14
“Monotherapy trials in this population that led to the U.S. Food and Drug Administration (FDA) approval, including teclistamab, The fl ow chart. elranatamab and talquetamab, achieved 40% to 74% ORR and 5.1 month to NR mPFS (18, 24, 28, 32, 33).”
BackgroundMethodInfluentialAntibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma
Tacchetti, P., Talarico, M., Barbato, S., Pantani, L., Mancuso, K., Rizzello, I., Zamagni, E., & Cavo, M. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2344647 · Cited by 16
“%) and favorable survival outcomes (median PFS between 9 and 14 months) have also been reported with ide-cel [69] and BsAbs [47,48,59], while belantamab mafodotin has shown lower efficacy when compared with these T-cell redirecting therapies, with approximately one-third of responsive patients and…”
BackgroundResultHartley-Brown, M. A., Weisel, K. C., Bitetti, J., Carter, J. A., McNamara, S., Purser, M. F., Palumbo, A., & Richardson, P. G. G. (2024) · British Journal of Haematology · doi:10.1111/bjh.19627 · Cited by 17
Kidney disease in multiple myeloma
Bridoux, F., Leung, N., Nasr, S. H., Jaccard, A., & Royal, V. (2024) · La Presse Médicale · doi:10.1016/j.lpm.2024.104264 · Cited by 15
Gerber, W. K., Xie, Y., & Patel, S. A. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00753 · Cited by 17
Jamet, B., Bodet‐Milin, C., Moreau, P., Kraeber‐Bodéré, F., & Touzeau, C. (2023) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004588 · Cited by 15
Self-citationA year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022
Kayki‐Mutlu, G., Aksoyalp, Z. Ş., Wojnowski, L., & Michel, M. C. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02465-x · Cited by 16
Hua, G., Scanlan, R., Straining, R., et al. (2023) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2023.14.2.7 · Cited by 15
“The median time until onset of ICANS was 4 days (range: 2–8 days) after the most recent dose with a median duration of 3 days (range: 1–20 days; Moreau et al., 2022).”
BackgroundMethodResultInfluentialHou, J., Li, Y., & Lin, Q. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00436-9 · Cited by 15
“However, bispecific antibodies (BsAbs) and dual-targeting chimeric antigen receptor T (CAR T) cells have shown good efficacy and safety in clinical scenarios [2] and can provide strong and durable responses [3].”
BackgroundElranatamab treatment in a multiple myeloma patient undergoing renal dialysis
de Wyngaert, Z. V., Romera, I., Chedeville, C., et al. (2024) · Clinical Hematology International · doi:10.46989/001c.116800 · Cited by 15
Teclistamab for relapsed refractory multiple myeloma patients on dialysis
Lebreton, P., Lachenal, F., Bouillie, S., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19772 · Cited by 15
Coffey, D. G., Atilla, P. A., Atilla, E., Landgren, O., Cowan, A. J., Simon, S., Pont, M. J., Comstock, M., Hill, G. R., Riddell, S. R., et al. (2024) · Blood · doi:10.1182/blood.2024025231 · Cited by 17
Fitness and frailty in myeloma
Pawlyn, C., Khan, A., & Freeman, C. L. L. (2022) · Hematology · doi:10.1182/hematology.2022000346 · Cited by 16
T-Cell Engagers — Modern Immune-Based Therapies for Multiple Myeloma
Mailankody, S., & Landgren, O. (2022) · New England Journal of Medicine · doi:10.1056/nejme2209692 · Cited by 16
How artificial intelligence revolutionizes the world of multiple myeloma
Romero, M. L., Orgueira, A. M., & Saldarriaga, M. M. (2024) · Frontiers in Hematology · doi:10.3389/frhem.2024.1331109 · Cited by 18
Scott, S. A., Roberts, D. L., Gupta, V. A., Joseph, N. S., Hofmeister, C. C., Dhodapkar, M. V., Lonial, S., Nooka, A. K., & Kaufman, J. L. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.04.002 · Cited by 16
Self-citationAdvances in the clinical application of bispecific antibodies in cancer therapy
Zhou, S., Feng, L., Niu, M., Wu, K., Li, T., & Yi, M. (2025) · iScience · doi:10.1016/j.isci.2025.114203 · Cited by 17
Krishnan, A. Y., Nooka, A. K., Chari, A., Garfall, A. L., Martin, T. G., Nair, S. C., Lin, X., Qi, K., Londhe, A., Pei, L., et al. (2023) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2022-0186 · Cited by 15
“Teclistamab was evaluated in the multicohort Phase I / II MajesTEC-1 (NCT03145181 / NCT04557098) trial in patients with RRMM who had received ≥ 3 prior LOTs and were TCE [13] .”
MethodSelf-citationThe expanding success of T cell-engaging bispecific antibodies
Bargou, R. C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00586-z · Cited by 14
Contejean, A., Janssen, C., Orsini‐Piocelle, F., Zecchini, C., Charlier, C., & Chouchana, L. (2023) · American Journal of Hematology · doi:10.1002/ajh.27071 · Cited by 15
Analysis of Updates in Multiple Myeloma Treatment and Management
Nieto, M. J., Hedjar, A., Locke, M., Caro, J., & Saif, M. W. (2023) · Journal of Clinical Haematology · doi:10.33696/haematology.4.055 · Cited by 14
“The studies in its development showed a high rate of profound and prolonged response [9].”
BackgroundBridging treatment prior to chimeric antigen receptor T‐cell therapy in multiple myeloma
Bal, S., & Costa, L. J. (2023) · British Journal of Haematology · doi:10.1111/bjh.19227 · Cited by 14
“25,26,29 Additionally, several platforms are optimizing the vein-to-vein time by streamlining the manufacturing and quality control processes of autologous CART-cell products while preserving the depth and durability of responses.”
BackgroundTerpos, E., Gavriatopoulou, M., Ntanasis‐Stathopoulos, I., Malandrakis, P., Fotiou, D., Migkou, M., Theodorakakou, F., Spiliopoulou, V., Kostopoulos, I. V., Syrigou, R., et al. (2024) · Haematologica · doi:10.3324/haematol.2023.284347 · Cited by 15
Impact of elranatamab on quality of life: Patient‐reported outcomes from MagnetisMM ‐3
Mohty, M., Bahlis, N. J., Nooka, A. K., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19346 · Cited by 14
“28,29 These types of PRO analysis are limited by the lack of a consensus on what PRO measure thresholds constitute clinically meaningful differences in MM studies, there being wide variability between studies in the definitions used.”
BackgroundSelf-citationSoltantabar, P., Sharma, S., Wang, D., Lon, H., Czibere, A. G., Hickman, A., & Elmeliegy, M. A. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3223 · Cited by 19
Metadata
- Authors
- Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., Karlin, L., Benboubker, L., Mateos, M.-V., Bahlis, N., Popat, R., Besemer, B., Martínez-López, J., Sidana, S., Delforge, M., Pei, L., Trancucci, D., Verona, R., Girgis, S., Lin, S. X. W., Olyslager, Y., Jaffe, M., Uhlar, C., Stephenson, T., Van Rampelbergh, R., Banerjee, A., Goldberg, J. D., Kobos, R., Krishnan, A., & Usmani, S. Z.
- Affiliations
- Karolinska University Hospital (SE)
- From the Hematology Clinic, University Hospital Hôtel-Dieu, Nantes (P.M.), Service d’Hématologie Clinique, Centre Hospitalier Lyon Sud, Pierre-Bénite (L.K.), and Service d’Hématologie et Thérapie Cellulaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire, Tours (L.B.) — all in France; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.L.G.), and Janssen Research and Development, Spring House (R.V., S.G., S.X.W.L., C.U., T.S., A.B.) — both in Pennsylvania; the Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam (N.W.C.J.D.); Karolinska University Hospital at Huddinge, Stockholm (H.N.); Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Investigación Sanitaria de Navarra, Pamplona (J.F.S.-M.), Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Puj...
- City Of Hope National Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-08-11
- Volume
- 387
- Issue
- 6
- Pages
- 495-505
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10587778
- OpenAlex
- W4282033105
- Cited by
- 1,269
- References
- 25
- Citations by year
- 2026: 335 · 2025: 341 · 2024: 320 · 2023: 231 · 2022: 39
- FWCI
- 169.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Lirias (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Janssen Research & Development, LLC
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- teclistamab, relapsed/refractory multiple myeloma, bispecific T-cell engagers, overall response rate, minimal residual disease negativity, progression-free survival, cytokine release syndrome, neurotoxicity, dose-limiting toxicity, subcutaneous administration, immunotherapy safety and efficacy
- MeSH terms
- Antineoplastic Agents, Immunological, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Humans, Injections, Subcutaneous, Multiple Myeloma, Neoplasm Recurrence, Local, Recurrence, T-Lymphocytes, CD3 Complex, Antibodies, Bispecific, B-Cell Maturation Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
